Experimental stages—effect on MDSC, in the context of TB, yet to be evaluated. Gefitinib has been shown to inhibit STAT3 which is crucial for the expansion of MDSC, making it a promising target for directed therapies. Murine and human infection model. Here, STAT3 is linked to tuberculosis.